QPPV.COM KNOWLEDGE ASSESSMENT

Tenofovir alafenamide: Discovery, Development, Safety and Pharmacovigilance

Test your understanding of the concepts covered by Tenofovir alafenamide: Discovery, Development, Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 A company uses sales for a multi-ingredient HIV regimen as evidence of the commercial performance of TAF alone. What is the main analytical problem?
Question 2 of 10 A reviewer sees lower plasma tenofovir concentrations with TAF than with TDF and concludes that TAF cannot cause renal injury. What is the most appropriate scientific response?
Question 3 of 10 In the HBV trials, TAF and TDF had similar reported suppression percentages in particular patient groups. Why are those percentages alone insufficient to claim superiority or equivalence?
Question 4 of 10 Which description best captures the pharmacological rationale for developing tenofovir alafenamide (TAF) rather than a new antiviral target?
Question 5 of 10 A patient develops renal abnormalities while taking a boosted TAF-containing regimen. Which approach best reflects the article's advice?
Question 6 of 10 A patient with HIV/HBV coinfection is to discontinue a TAF-containing HIV regimen. What is the key pharmacovigilance and clinical concern identified in the article?
Question 7 of 10 Which statement best distinguishes a favourable bone mineral density result from a demonstrated reduction in fracture risk?
Question 8 of 10 What is the strongest interpretation of the pivotal HIV studies comparing TAF- and TDF-containing regimens?
Question 9 of 10 Which statement correctly distinguishes the EU authorisations discussed for Vemlidy and Biktarvy?
Question 10 of 10 Which information is most useful when assessing a suspected hepatic event after discontinuation of HBV-active treatment?

Select an answer to continue.

QPPV.com